Tags : Enters


Genentech Signs an Exclusive License Agreement with X-Chem to Discover

Shots: X-Chem to receive an up front and is eligible to receive research, development and regulatory milestone along with royalties on sales of therapies resulting from the collaboration Genentech will lead further development and commercialization of any potential new therapies and retain exclusive rights to compounds derived from the collaboration. Additionally, Genentech get an exclusive […]Read More


Amazon Enters into Fitness Space with the Launch of Halo

Shots: Amazon launches the Halo fitness band and a subscription service by the same name. The smart band combines a suite of AI-powered health tool with an innovative and stylish wrist band Halo band and subscription service unlock an array of health metrics, including activity, sleep, body fat, and tone of voice analysis, to determine […]Read More


Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to

Shots: Orionis to receive research funding, convertible notes, clinical milestones along with royalties while Novartis gets access to Orionis’ Allo-Glue technology platform for designing novel therapies like protein degraders across multiple therapeutic areas The collaboration will combine Novartis’ expertise in drug discovery and development with Orionis’ innovative technologies for identifying and prioritizing new targets at […]Read More


MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for

Shots: MSD to supply Keytruda (pembrolizumab) to I-Mab to utilize it in clinical studies in combination with its TJC4. The companies will collaborate to evaluate PK/PD & preliminary efficacy of dual regimen for multiple cancer indications in a P-I study The collaboration will further explore the therapeutic potential of combination therapy, TJC4 with Keytruda across […]Read More


Vertex Signs an Access Agreement with Scottish Government for Orkambi

Shots: The access agreement allows patients with eligible cystic fibrosis to access Orkambi and Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor in Scotland Vertex will collect real-world data on the combination therapies which will support future regulatory submission to the Scottish Medicines Consortium (SMC) following the 5yrs. access agreement Orkambi is a combination therapy used to […]Read More